DGDermot Gleeson

Dermot Gleeson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dermot Gleeson has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diabetes Mellitus in Patients With Autoimmune Hepatitis: Frequency, Risk Factors and Effect on Outcome

    by Sarah Flatley, Selena Dixon, Eleanor Pilsworth, Asha Dube, Barbara Hoeroldt, Laura Harrison, Dermot Gleeson

    Background: Treatment for autoimmune hepatitis (AIH) includes corticosteroids, which are associated with the development of diabetes mellitus (DM). Reported new‐onset DM rates in patients with AIH have varied, and predisposing factors and prognostic implications are inadequately characterised.Aim: To identify the frequency and predisposing factors for DM in AIH and its association with disease progression and mortality.Methods: Retrospective/prospective single‐centre study of 494 patients with AIH presenting 1987–2023, 466 receiving corticosteroids (454 prednisolone, 12 budesonide) and followed for (median (range) 9 (0–36) years).Results: Forty‐seven patients (10%) already had DM at AIH diagnosis. New‐onset DM subsequently developed in another 59 (13%). In those receiving prednisolone, new‐onset DM incidence was 8% ± 1% after 1 year and 14% ± 2% after 10 years (14‐ and 3‐fold higher than expected population rate), and was independently associated with older age, non‐Caucasian ethnicity, higher initial prednisolone dose, higher BMI at diagnosis and more weight gain after 2 years of follow‐up. New‐onset DM usually persisted despite stopping prednisolone.New‐onset DM and DM at any time were independently associated with all‐cause death/transplantation rate, along with previously established risk factors (older age, cirrhosis, lower ALT at diagnosis and failure of early ALT normalisation). New‐onset DM and DM at any time were also independently associated with cirrhosis development. Similar associations of new‐onset DM and DM at any time with liver‐related death/transplantation were significant on univariate but not multivariate analysis.Conclusion: New‐onset DM occurred in 13% of patients with AIH, was related to older age, non‐Caucasian ethnicity, higher prednisolone dose, higher BMI at diagnosis and weight gain; and was an independent predictor of all‐cause death/transplantation and of cirrhosis development, underlining the need to minimise steroid burden in AIH.


  • Open Access

    British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis

    by Dermot Gleeson, Rosemary Bornand, Ann Brownlee, Harpreet Dhaliwal, Jessica K Dyson, Janeane Hails, Paul Henderson, Deirdre Kelly, George F Mells, Rosa Miquel, et al.

    Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease which, if untreated, often leads to cirrhosis, liver failure and death. The last British Society of Gastroenterology (BSG) guideline for the management of AIH was published in 2011. Since then, our understanding of AIH has advanced in many areas. This update to the previous guideline was commissioned by the BSG and developed by a multidisciplinary group. The aim of this guideline is to review and summarise the current evidence, in order to inform and guide diagnosis and management of patients with AIH and its variant syndromes. The main focus is on AIH in adults, but the guidelines should also be relevant to older children and adolescents.


  • Open Access

    What is the optimal first-line treatment of autoimmune hepatitis? A systematic review with meta-analysis of randomised trials and comparative cohort studies

    by Dermot Gleeson, Marrissa Martyn-StJames, Ye Oo, Sarah Flatley

    Objectives Uncertainty remains about many aspects of first-line treatment of autoimmune hepatitis (AIH). Design Systemic review with meta-analysis (MA). Data sources Bespoke AIH Endnote Library, updated to 30 June 2024. Eligibility criteria Randomised controlled trials (RCTs) and comparative cohort studies including adult patients with AIH, reporting death/transplantation, biochemical response (BR) and/or adverse effects (AEs). Data extraction and synthesis Data pooled in MA as relative risk (RR) under random effects. Risk of bias (ROB) assessed using Cochrane ROB-2 and ROBINS-1 tools. Results From seven RCTs (five with low and two with some ROB) and 18 cohort studies (12 moderate ROB, six high for death/transplant), we found lower death/transplantation rates in (a) patients receiving pred+/−aza (vs no pred): overall (RR 0.38 (95% CI 0.20 to 0.74)), in patients without symptoms (0.38 (0.19–0.75)), without cirrhosis (0.30 (0.14–0.65)), and with decompensated cirrhosis (RR 0.38 (0.23–0.61)), and (b) patients receiving pred+aza (vs pred alone) (0.38 (0.22–0.65)). Patients receiving higher (vs lower) initial pred doses had similar BR rates (RR 1.07 (0.92–1.24)) and mortality (0.71 (0.25–2.05)) but more AEs (1.73 (1.17–2.55)). Patients receiving bud (vs pred) had similar BR rates (RR 0.99 (0.71–1.39)), with fewer cosmetic AEs (0.46 (0.34–0.62)). Patients receiving mycophenolate mofetil (MMF) (vs aza) had similar BR rates (RR 1.32 (0.73–2.38)) and fewer AEs requiring drug cessation (0.20 (0.09–0.43)). Conclusions Mortality is lower in pred-treated (vs untreated) patients, overall and in several subgroups, and in those receiving pred+aza (vs pred). Higher initial pred doses confer no clear benefit and cause more AEs. Bud (vs pred) achieves similar BR rates, with fewer cosmetic AEs. MMF (vs aza) achieves similar BR rates, with fewer serious AEs.


  • Surveillance for cholangiocarcinoma in patients with primary sclerosing cholangitis: Can we be more proactive?

    by Dermot Gleeson, Martine Walmsley, Palak J Trivedi, Deepak Joshi, Ben Rea


  • Open Access

    Histopathologist and clinician interface in diagnosis and management of autoimmune hepatitis

    by Sarah Flatley, Asha K Dube, Dermot Gleeson

    Diagnosis of AIH is based on a combination of clinical, laboratory and histological information. It has been formalised by diagnostic scoring systems, to which liver biopsy contributes substantially. Diagnostic biopsy is thus, desirable in nearly all patients. An adequate biopsy size, provision by clinicians of adequate information to histopathologists and active discussion at regular meetings are all important for accurate histological diagnosis. Recently, the specificity of some features previously thought to suggest AIH has been questioned, and new recommendations for histological diagnosis have been proposed, although not yet validated. The histology of acutely presenting AIH and that of severe or fulminant AIH include some characteristic features. Primary biliary cholangitis, primary sclerosing cholangitis and non-alcoholic fatty liver disease may co-exist with AIH on biopsy. Liver biopsy also enables grading of severity of inflammation and staging of fibrosis. Presence of cirrhosis is a poor prognostic marker. Repeat liver biopsy after achieving biochemical remission, although not performed routinely, enables assessment of (a) histological remission, a favourable prognostic indicator and (b) fibrosis progression. It can thus help determine further management.


  • A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers

    by John B. Whitfield, Tae-Hwi Schwantes-An, Rebecca Darlay, Guruprasad P. Aithal, Stephen R. Atkinson, Ramon Bataller, Greg Botwin, Naga P. Chalasani, Heather J. Cordell, Ann K. Daly, et al.


  • Natural history of histologically proven alcohol-related liver disease: A systematic review

    by Richard Parker, Guruprasad P. Aithal, Ulrik Becker, Dermot Gleeson, Steven Masson, Judith I. Wyatt, Ian A. Rowe


  • Open Access

    Grand round: Autoimmune hepatitis

    by Palak J. Trivedi, Stefan G. Hubscher, Michael Heneghan, Dermot Gleeson, Gideon M. Hirschfield


  • Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)?

    by Laura Harrison, Dermot Gleeson

    Background: Initial treatment of autoimmune hepatitis (AIH) with prednisolone ± azathioprine is based on randomised controlled trials. Many patients receive long‐term immunosuppressive treatment to prevent disease relapse; this strategy has a weaker evidence base.Aim: To consider whether immunosuppressive treatment (IST) withdrawal in AIH is justified and to develop a rationale for patient selection.Methods: We reviewed published papers between 1972 and 2018, which addressed the outcomes of IST withdrawal and/or complications of IST in AIH.Results: (1) AIH relapse rates after withdrawal of IST vary between 25% and 100%. There is heterogeneity in these studies regarding relapse definition, IST duration prior to withdrawal and criteria for biochemical and histological remission prior to withdrawal. (2) Factors associated with relapse following IST withdrawal include: (a) absence of an identifiable initial disease trigger, (b) presence of other autoimmune diseases, (c) longer time to biochemical remission and (d) elevated serum transaminases on treatment withdrawal. Reports of associations between relapse and age, IST duration and failure of histological remission have been inconsistent. (3) Continued IST reduces risk of AIH relapse over at least 5 years. However, there is no evidence that routine (as opposed to selective) long‐term IST improves disease outcome. (4) Patients with AIH have an increased risk of extrahepatic cancer, notably non‐melanoma skin cancer, to which long‐term IST may contribute. Long‐term corticosteroid therapy is associated with weight gain, low‐trauma fractures, diabetes and possibly vascular disease.Conclusions: While further studies are needed, evidence supports a strategy of IST withdrawal in some patients with AIH who have achieved remission.